查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854526

胃癌治疗市场按治疗类型、给药途径、分销管道、分期、最终用户和组织学类型划分－2025-2032年全球预测

Stomach Cancer Treatment Market by Treatment Type, Route Of Administration, Distribution Channel, Stage, End User, Histologic Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，胃癌治疗市场规模将达到 117.9 亿美元，复合年增长率为 9.88%。

主要市场统计数据
基准年 2024 55.5亿美元
预计年份：2025年 61亿美元
预测年份：2032年 117.9亿美元
复合年增长率 (%) 9.88%

全面了解胃癌治疗领域不断演变的动态、未满足的临床需求、治疗创新以及影响治疗实践的相关人员的优先事项。

胃癌治疗正处于曲折点，数十年的渐进式改进与新一轮的治疗创新和医疗体系重组在此交汇。患者、临床医生和支付者需要应对日益复杂的治疗方法，这些方案融合了手术和化疗等传统疗法，以及标靶药物、免疫肿瘤疗法和先进的放射治疗技术。因此，我们需要建构以病人为中心的临床决策树，整合组织学分型、分子谱分析、给药途径和治疗环境等因素。

此外，治疗方法理念正从单一治疗方法的优越性转向多治疗方法序列和组合方案，这需要跨部门协作和完善的临床指南。治疗方法，监管预期和报销机制也在不断演变，更加重视真实世界证据、已证实的价值和卫生经济学模型。在营运层面，随着口服药物和居家照护支援的普及，医疗服务提供者必须调整住院和门诊容量规划，以适应使用模式的变化。同时，临床研究的重点转向预测腺癌、胃肠道基质肿瘤和其他组织学变异体疗效的生物标记物，这促使人们在检测设计和居家照护标靶选择方面采取更细緻入微的方法。

综上所述，这些动态既为寻求在资源有限的情况下优化患者疗效的相关人员带来了紧迫性和机会。展望未来，技术创新的发展轨迹很可能取决于临床证据、支付方框架和医疗服务体系在多大程度上能够支持个人化、可及且可持续的胃癌治疗。

科学突破、不断发展的管理实践和医疗保健系统趋势如何重塑胃癌治疗的临床管道和投资重点

胃癌治疗格局正因科学突破、临床实践的演进以及治疗模式的转变而改变。精准医学的进步加速了可标靶治疗标靶的识别，并为将EGFR、HER2和VEGF抑制剂等标靶治疗纳入标准治疗方案创造了机会。同时，包括CTLA-4和PD-1抑制剂在内的免疫疗法药物正在改变人们对特定患者持久疗效的预期，促使人们重新调整终点选择和长期预后指标。

同时，临床实务也在适应新的给药途径和环境。口服製剂的日益普及正在影响患者的依从性监测和门诊病人管理，而近距离放射治疗和体外放射治疗等放射治疗方式也正透过影像导引技术的改进而变得更加精准。外科治疗也不断发展，部分胃切除术和全切除术的选择变得更加细緻，需要根据肿瘤位置、疾病分期和患者合併症等因素来权衡。这些治疗方式的转变与更广泛的医疗保健系统趋势相交织，包括数位化健康监测、居家医疗服务的扩展以及药房管道的多元化，涵盖医院、零售和线上管道。

最终，最重大的变革将发生在科学创新、监管灵活性和支付方合作三者汇聚之处，从而促成​​具有临床意义的治疗方法的及时推出。能够预见这些曲折点并落实跨部门准备工作的相关人员，将更有能力把治疗方法进展转化为改善患者预后和实现可持续的医疗服务。

对近期美国关税调整如何影响胃癌治疗药物供应链韧性、筹资策略和采购实践进行定性分析

政策变革和贸易行动会对药品供应链、采购成本和生产商定价策略产生连锁反应，并可能对治疗药物的可近性和可近性产生重大影响。美国近期提出的关税提案和调整促使企业在考虑短期成本差异之外，重新检视供应商多元化、合约条款和库存策略。由于许多活性药物原料药和最终产品依赖全球生产网络，关税带来的成本压力可能会加速企业重新置换製造地、寻找替代供应商或重新谈判长期合约以降低投入成本波动的进程。

在实务中，医疗系统和药局管道必须权衡潜在的成本影响与优先保障医疗服务连续性的临床需求。例如，如果某些静脉注射药物的进口管道受到影响，医院和专科诊所可能会考虑调整采购窗口、增加库存储备，并探索替代治疗方法以避免治疗中断。同时，面临进口成本上涨的生产商可能会重新考虑其定价策略、折扣策略和市场优先顺序，这将影响与支付方的谈判以及药品目录的收录。

除了直接的采购影响外，关税还能促成策略转变，例如加速对国内製造业产能的投资、重组分销网络以利于建立更具韧性的国内供应链，以及与风险共担的供应商和大型采购组织开展更紧密的合作。这些适应性因应措施将受到监管机构和支付方讯号的限制，这些讯号决定了关税措施的时机和持续时间，以及替代采购和国内製造业投资的临床和商业性可行性。

详细的細項分析展示了治疗方式、给药途径、分销管道、疾病阶段、最终用户和组织学类型如何决定治疗和商业策略。

细緻的细分视角揭示了治疗决策和商业策略如何必须与临床异质性和治疗格局相契合。治疗方式涵盖化疗、免疫疗法、放射线治疗、手术和标靶治疗，每种疗法都包含具有临床意义的亚群。化疗包括基于Fluorouracil、铂类和紫杉烷类的方案，而免疫疗法则根据其是否为CTLA-4抑制剂和PD-1抑制剂而有所区别。放射线治疗包括近距离放射疗法和体外放射治疗，手术选择从切除术胃切除术到全胃切除术。标靶治疗的差异体现在针对EGFR、HER2和VEGF通道的药物。这些治疗方式的差异会影响临床治疗顺序、不利事件管理以及主导生物标记的患者选择。

给药途径进一步影响患者的依从性、给药成本和治疗场所的选择，静脉注射注射和口服给药途径需要不同的监测和支持。分销管道，包括医院、线上药房和零售药房，决定了药物获取模式、配药控制和报销流程；而从I期到IV期的特定阶段性因素则指导着治疗意向和姑息治疗优化之间的平衡。最终使用者包括居家医疗、医院和专科诊所，它们各自存在容量限制和护理协调模式，这些都会影响治疗方法的采纳。组织学多样性——腺癌、类癌、胃肠道基质肿瘤和淋巴瘤——增加了临床鑑别的层次，为实验室合格和治疗标靶的选择提供了基础。

细分市场分析表明，商业策略和临床指南必须高度契合。为了在异质性医疗生态系统中实现最大的临床影响和营运契合度，製造商和医疗服务提供者应使产品开发和交付模式与特定疗法的疗效特征、给药途径和分销实际情况相符。

对美洲、欧洲、中东和非洲以及亚太地区的支付方结构、监管管道和医疗服务能力如何影响治疗方案的采纳和可及性进行区域分析。

区域临床实务模式、监管管道和医疗保健系统资金筹措影响着胃癌治疗方法的研发、核准和应用。在美洲，临床应用受到多种因素的影响，包括公立和私立支付方、不断演变的价值框架以及推动高成本标靶药物和免疫肿瘤药物早期应用的卓越中心。该地区的医疗机构通常重视疗效评估和真实世界证据的生成，以支持报销谈判并优化上市后应用。

欧洲、中东和非洲地区（EMEA）各市场监管协调和报销流程的差异，造就了错综复杂的市场进入动态。有些国家优先考虑国家卫生技术评估框架，要求进行严格的卫生经济学论证；而有些国家则强调新型疗法的快速进入机制。这些差异导致製造商在不同地区采取不同的市场进入策略和定价策略，反映了各地不同的经济承受能力和优先事项。

在亚太地区，人口结构变化、肿瘤治疗基础设施的不断改进以及诊断能力的提升，正在加速推动对生物标记主导治疗和门诊口服疗法的需求。区域製造地和监管管道的演变也影响采购和分销方式。综上所述，这些地域差异凸显了製定国家层级策略的重要性，这些策略需要协调临床证据、监管时机、支付方预期以及本地供给能力，以实现持续的药物可近性和普及应用。

对决定胃癌治疗药物研发、取得和推广成败的竞争动态、竞争模式和商业化重点进行策略概述

胃癌治疗领域的竞争动态反映了一个由历史悠久的传统企业、专业生物技术创新者以及涵盖学术中心和合约研究机构的协力网路组成的多方位生态系统。传统企业不断透过扩展适应症、调整治疗方案定位以及将标靶药物与细胞毒性药物和免疫调变器联合应用等策略来优化其现有产品组合。同时，中小型创新企业正在推进以机制主导的候选药物研发，这些药物针对特定的分子亚群，并利用富含生物标记的检测设计来证明其差异化的临床效用。

策略伙伴关係和授权协议在缩短研发週期和扩大地域覆盖范围方面发挥核心作用。此外，结合临床专业知识和商业化能力的共同开发契约有助于降低后期研发专案的风险，并有助于进入专业分销管道。同时，专注于患者支持、诊断和数位依从性工具的服务供应商正成为治疗价值提案不可或缺的一部分，尤其是在口腔和居家照护模式下。

从商业角度来看，定价策略、证据产生和支付方参与之间的相互作用至关重要。那些投资于可靠的真实世界证据收集、卫生经济学建模和相关人员教育的公司，更有利于获得有利的药品目录排名，并在不同的医疗环境中展现其价值。最终，竞争优势将取决于能否在多个管道和地区大规模地提供具有临床意义的疗效，同时控製成本和营运复杂性。

为开发商、支付方和医疗服务提供者提供切实可行的、优先排序的建议，以协调临床开发、供应链弹性和商业化，从而产生可衡量的影响。

行业领导者必须采取务实且具有前瞻性的倡议，将科学进步转化为可持续的临床和商业性成果。首先，将临床开发计画与生物标记主导的患者选择和适应性临床试验架构结合，可以提高证明疗效显着的可能性，同时节省资源。製造商还应积极设计证据生成项目，涵盖随机对照试验和真实世界试验，以满足不同司法管辖区监管机构和支付方的期望。

在营运层面，投资供应链韧性可以降低全球采购和关税波动带来的风险。这包括供应商网路多元化、加强库存管理，以及在可行的情况下探索本地製造伙伴关係。商业团队应根据药物的给药方式和途径调整其市场推广策略，认识到口服药物需要更强的依从性和患者支持体系，而静脉注射和手术治疗方法则依赖于医院和专科诊所的准备情况。与医院、线上和零售药房等管道的分销合作伙伴合作，对于确保患者能够顺畅地获得药物至关重要。

最后，应儘早进行跨相关人员合作，将诊断、数位健康工具和支付方参与整合到研发过程中。建立引人注目的健康经济模型并收集长期结果数据，有助于促进与支付方的对话，并支持差异化市场定位。透过执行这些策略重点，领导者既可以改善患者预后，又能确保可持续的商业管道。

结合专家访谈、临床文献回顾和跨细分市场分析的稳健混合方法研究途径，能够得出有效且可操作的见解。

本分析的调查方法结合了多源证据综合和同侪检验的解读，以确保其严谨性。主要资料来源包括对肿瘤科医生、药房主任、支付方代表和临床营运负责人进行的结构化访谈，以了解真实世界的诊疗模式、应用障碍和证据需求。次要资料来源包括同行评审的临床文献、临床试验註册库、监管指导文件和公开提交的信息，以构建治疗机制、安全性特征和试验终点的准确整体情况。

分析技术包括交叉分割映射，以将治疗方式与给药途径、分销管道、疾病阶段、最终用户状态和组织学亚型相匹配。情境分析和敏感性检定用于检验有关供应链中断和政策变化的假设。在条件允许的情况下，研究结果透过多个资料来源进行三角验证，并透过专家咨询检验。

调查团队严格遵循透明的资料来源记录、访谈通讯协定和研究前提条件，以确保研究结果的可重复性并支援客户客製化需求。出于伦理考量，研究团队积极鼓励相关人员参与，所有原始资料收集都采取了适当的保密措施。这项方法论基础为相关人员在不断变化的胃癌治疗领域中寻求切实可行的见解提供了有力支持。

总结报告强调，需要整合临床、商业和营运策略，才能将创新转化为可近且可持续的胃癌治疗。

胃癌治疗正朝着更个人化、多重模式的治疗模式发展，需要临床证据、供应链、支付框架和医疗服务体系之间的协调配合。标靶治疗和免疫肿瘤学的进步正在创造新的临床可能性，但要充分发挥这些潜力，取决于对诊断、患者支持和真实世界证据生成的协调投入。此外，给药途径、分销管道和区域监管差异等营运因素也会对推广应用的速度和范围产生重大影响。

积极将科学策略与切实可行的商业化和供应链计划相结合的相关人员，最有可能在改善治疗效果方面取得显着成效。这需要一种整体视角，既要考虑组织学异质性、疾病阶段和最终用户的能力，又要预测影响治疗可及性的政策和贸易观点。简而言之，成功与否取决于能否将治疗潜力转化为可及且经济可持续的治疗途径。

随着这一领域的不断发展，持续监测临床试验结果、监管决策和实际应用表现对于完善策略、抓住差异化治疗方法的机会至关重要。将严谨的科学研究与灵活的运作能力结合，确保最需要的患者能够公平地获得创新疗法，才是未来的发展方向。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • PD-1和PD-L1抑制剂在胃癌一线治疗的快速应用
  • 将分子生物标记筛检应用于胃癌个人化治疗
  • 液态生物检体在肿瘤復发早期检测和监测的应用日益广泛
  • 针对伴随受体扩增的晚期胃癌患者，开发FGFR2标靶药物
  • 扩大微创机器人手术的应用范围，以改善胃癌术后疗效
  • 利用真实世界证据优化转移性胃癌的治疗顺序
  • 扩大免疫疗法和化疗联合治疗治疗晚期胃癌的方案
  • 增加对人工智慧内视镜系统的投资，以提高胃癌的早期诊断率
  • 针对 Claudin 18.2 的 CAR-T 细胞疗法在难治性胃癌的应用
  • 不断变化的健保报销政策将如何影响各市场获得新型胃癌疗法的机会

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 胃癌治疗市场依治疗类型划分

  • 化疗
    • 基于Fluorouracil的
    • 铂金基底
    • 紫杉烷类
  • 免疫疗法
    • Ctla-4抑制剂
    • Pd-1抑制剂
  • 放射线治疗
    • 近距离放射治疗
    • 外樑
  • 外科手术
    • 部分切除术
    • 全胃切除术
  • 标靶治疗
    • EGFR抑制剂
    • HER2抑制剂
    • VEGF抑制剂

9. 依给药途径分類的胃癌治疗市场

  • 静脉
  • 口服

第十章 胃癌治疗市场依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 胃癌治疗市场（依分期划分）

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第十二章 依最终用户分類的胃癌治疗市场

  • 居家医疗
  • 医院
  • 专科诊所

第十三章 依组织类型分類的胃癌治疗市场

  • 腺癌
  • 类癌肿瘤
  • 胃肠道基质肿瘤
  • 淋巴瘤

第十四章 各地区胃癌治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 胃癌治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国胃癌治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb Company
    • Merck Sharp & Dohme Corp.
    • AstraZeneca PLC
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Daiichi Sankyo Company, Limited
    • Sanofi SA
    • Pfizer Inc.
    • Amgen Inc.
Product Code: MRR-F927BA461E32

The Stomach Cancer Treatment Market is projected to grow by USD 11.79 billion at a CAGR of 9.88% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.55 billion
Estimated Year [2025] USD 6.10 billion
Forecast Year [2032] USD 11.79 billion
CAGR (%) 9.88%

A comprehensive orientation to evolving stomach cancer treatment dynamics, unmet clinical needs, therapeutic innovation, and stakeholder priorities shaping care practices

Stomach cancer treatment is at an inflection point where decades of incremental improvements intersect with a new cadence of therapeutic innovation and health system recalibration. Patients, clinicians, and payers are navigating increasingly complex care pathways that combine traditional modalities such as surgery and chemotherapy with expanding use of targeted agents, immuno-oncology therapies, and advanced radiotherapeutic techniques. As a result, clinical decision trees now require integration of histologic subtyping, molecular profiling, and patient-centered considerations including route of administration and care setting.

Moreover, the therapeutic conversation is shifting from single-modality dominance toward multi-modality sequencing and combination regimens, which demand cross-disciplinary coordination and refined clinical guidelines. This shift is accompanied by evolving regulatory expectations and reimbursement mechanisms that place greater emphasis on real-world evidence, value demonstration, and health economic models. Operationally, providers must reconcile inpatient and outpatient capacity planning as oral agents and homecare support change utilization patterns. In parallel, clinical research priorities are emphasizing biomarkers that predict response across adenocarcinoma, gastrointestinal stromal tumors, and other histologic variants, prompting a more granular approach to trial design and therapeutic targeting.

Taken together, these dynamics create both urgency and opportunity for stakeholders aiming to optimize patient outcomes while managing resource constraints. Looking ahead, the trajectory of innovation will be shaped by how well clinical evidence, payer frameworks, and delivery systems align to support personalized, accessible, and sustainable stomach cancer care.

How scientific breakthroughs, evolving administration practices, and health system trends are reshaping clinical pathways and investment priorities for stomach cancer care

The landscape of stomach cancer treatment is being transformed by a confluence of scientific breakthroughs, clinical practice evolution, and systemic shifts in care delivery. Precision medicine advances have accelerated the identification of actionable targets, creating opportunities for targeted therapies such as EGFR, HER2, and VEGF inhibitors to be integrated into standard regimens. At the same time, immunotherapy agents, including CTLA-4 and PD-1 inhibitors, are reshaping expectations for durable responses in subsets of patients, prompting recalibration of endpoint selection and long-term outcome measurement.

Concurrently, clinical practice is adapting to new administration routes and settings: the increasing adoption of oral formulations has implications for adherence monitoring and outpatient management, while radiotherapy modalities like brachytherapy and external beam are being refined through image-guided techniques that enhance precision. Surgical practice is also evolving, with nuanced decisions between partial and total gastrectomy informed by tumor location, stage, and patient comorbidity. These therapeutic shifts intersect with broader health-system trends such as digital health-enabled monitoring, expanded homecare capabilities, and pharmacy channel diversification that includes hospital, retail, and online options.

Ultimately, the most consequential transformations will emerge where scientific innovation, regulatory flexibility, and payer alignment converge to enable timely adoption of clinically meaningful therapies. Stakeholders who anticipate these inflection points and operationalize cross-functional readiness will be best positioned to translate therapeutic advances into improved patient outcomes and sustainable care delivery.

Qualitative analysis of how recent U.S. tariff adjustments are influencing supply chain resilience, sourcing strategies, and procurement practices across stomach cancer therapeutics

Policy changes and trade measures can ripple through drug supply chains, procurement costs, and manufacturer pricing strategies in ways that materially affect availability and access to therapies. Recent tariff proposals and adjustments in the United States have introduced considerations that extend beyond immediate cost differentials to include supplier diversification, contracting terms, and inventory strategies. Because many active pharmaceutical ingredients and finished products rely on global manufacturing networks, tariff-driven cost pressures can accelerate efforts to reshore manufacturing, secure alternative suppliers, or renegotiate long-term agreements to cap input volatility.

In practice, health systems and pharmacy channels must weigh potential cost implications against clinical imperatives that prioritize continuity of care. For example, if certain intravenous agents are sourced through affected import routes, hospitals and specialty clinics may consider adjusting procurement windows, increasing buffer stocks, or seeking therapeutic alternatives to avoid treatment disruptions. Simultaneously, manufacturers facing higher import costs may re-evaluate pricing strategies, discounting tactics, or market prioritization decisions, which in turn influence payer negotiations and formulary placement.

Beyond immediate procurement effects, tariffs can catalyze strategic shifts such as accelerated investment in local manufacturing capacity, restructured distribution footprints that favor resilient domestic supply chains, and closer collaboration between suppliers and large buying entities to share risk. These adaptive responses will be shaped by the timing and permanence of tariff measures, as well as by parallel regulatory and payer signals that determine clinical and commercial feasibility for alternative sourcing or domestic production investments.

In-depth segmentation analysis showing how modality, administration route, distribution channel, disease stage, end user, and histologic type jointly determine therapeutic and commercial strategies

A nuanced segmentation lens reveals how therapeutic decisions and commercial strategies must align with clinical heterogeneity and care settings. Treatment modalities span chemotherapy, immunotherapy, radiotherapy, surgery, and targeted therapy, and each modality contains clinically meaningful subgroups; chemotherapy encompasses fluorouracil-based, platinum-based, and taxane-based regimens, while immunotherapy is distinguished by CTLA-4 and PD-1 inhibitor classes. Radiotherapy practice includes brachytherapy and external beam approaches, and surgical options range from partial gastrectomy to total gastrectomy. Targeted therapy differentiation reflects agents directed at EGFR, HER2, and VEGF pathways. These modality-specific distinctions influence clinical sequencing, adverse event management, and biomarker-driven patient selection.

Route of administration further shapes adherence, administration costs, and care setting decisions, with intravenous and oral pathways creating distinct monitoring and support needs. Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy determine access patterns, dispensing controls, and reimbursement workflows, while stage-specific considerations across Stage I through Stage IV guide the balance between curative intent and palliative optimization. End users encompass homecare, hospitals, and specialty clinics, each with unique capacity constraints and care coordination models that affect therapy adoption. Histologic diversity-adenocarcinoma, carcinoid tumors, gastrointestinal stromal tumors, and lymphoma-adds another layer of clinical differentiation that informs trial eligibility and therapeutic targeting.

Taken together, segmentation insights indicate that commercial strategies and clinical guidelines must be highly tailored. Manufacturers and providers should align product development and delivery models with the modality-specific efficacy profile, administration route, and distribution realities to achieve the greatest clinical impact and operational fit within heterogeneous care ecosystems.

Regional analysis of how payer structure, regulatory pathways, and delivery capacity in the Americas, Europe Middle East & Africa, and Asia-Pacific shape treatment adoption and access

Regional patterns in clinical practice, regulatory pathways, and health-system financing shape how therapies for stomach cancer are developed, approved, and delivered. In the Americas, clinical adoption is influenced by a mix of private and public payers, evolving value frameworks, and concentrated centers of excellence that drive early uptake of high-cost targeted and immuno-oncology agents. Providers in this region often emphasize outcome measurement and real-world evidence generation to support reimbursement discussions and to optimize post-market utilization.

In Europe, the Middle East & Africa region, regulatory harmonization across markets and divergent reimbursement processes create a mosaic of access dynamics. Some jurisdictions prioritize national health technology assessment frameworks that require rigorous health economic demonstration, while others emphasize expedited access mechanisms for novel therapies. These differences lead manufacturers to adopt regionally differentiated market entry tactics and pricing strategies to reflect heterogeneous affordability and prioritization.

Across Asia-Pacific, demographic trends, growing oncology infrastructure, and expanding diagnostic capabilities are accelerating demand for biomarker-driven treatments and oral therapies that can be managed in outpatient settings. Regional manufacturing hubs and evolving regulatory pathways also influence procurement and distribution approaches. Collectively, these geographic distinctions underline the importance of tailored country-level strategies that reconcile clinical evidence, regulatory timing, payer expectations, and local delivery capacity to achieve sustained access and uptake.

A strategic overview of competitive dynamics, partnership models, and commercialization priorities that determine success across development, access, and scale for stomach cancer therapies

Competitive dynamics in stomach cancer treatment reflect a multifaceted ecosystem of long-established incumbents, specialty biotech innovators, and collaborative networks spanning academic centers and contract research organizations. Established players continue to optimize existing portfolios through label expansions, line-of-therapy positioning, and combination strategies that pair targeted agents with cytotoxic backbones or immune modulators. At the same time, smaller and mid-size innovators are advancing mechanism-driven candidates that address specific molecular subgroups, leveraging biomarker-enriched trial designs to demonstrate differentiated clinical benefit.

Strategic partnerships and licensing agreements remain central to accelerating development timelines and expanding geographic reach, particularly where regulatory heterogeneity demands localized trials or bridging studies. Moreover, co-development arrangements that blend clinical expertise with commercialization capabilities help de-risk late-stage programs and enable access to specialized distribution channels. Parallel to these collaborations, service providers focused on patient support, diagnostics, and digital adherence tools are becoming integral to therapeutic value propositions, especially for oral agents and homecare models.

From a commercialization perspective, the interplay between pricing strategy, evidence generation, and payer engagement is critical. Companies that invest in robust real-world evidence collection, health economic modeling, and stakeholder education are better positioned to secure favorable formulary placement and to demonstrate value across diverse care settings. Ultimately, competitive success will hinge on the ability to deliver clinically meaningful outcomes at scale while managing cost and operational complexity across multiple channels and regions.

Practical and prioritized recommendations for developers, payers, and providers to align clinical development, supply resilience, and commercialization for measurable impact

Industry leaders must adopt pragmatic, forward-looking moves to translate scientific advances into durable clinical and commercial outcomes. First, aligning clinical development plans with biomarker-driven patient selection and adaptive trial architectures can increase the probability of demonstrating meaningful benefit while conserving resources. Manufacturers should also proactively design evidence-generation programs that encompass both randomized controlled trials and real-world studies to satisfy regulatory and payer expectations across jurisdictions.

Operationally, investing in supply chain resilience will mitigate risks associated with global sourcing and tariff-induced disruptions; this includes diversifying supplier networks, enhancing inventory management, and exploring localized manufacturing partnerships where feasible. Commercial teams should tailor go-to-market approaches by modality and administration route, recognizing that oral agents may require more robust adherence and patient support infrastructure, whereas intravenous or surgical-centric therapies depend on hospital and specialty clinic readiness. Engagement with distribution partners across hospital pharmacy, online pharmacy, and retail pharmacy channels must be synchronized to ensure seamless patient access.

Finally, pursue cross-stakeholder collaborations that integrate diagnostics, digital health tools, and payer engagement early in development. Building compelling health economic models and collecting longitudinal outcomes data will facilitate payer conversations and support differentiated positioning. By executing these strategic priorities, leaders can improve patient outcomes while securing sustainable commercial pathways.

Robust mixed-methods research approach combining expert interviews, clinical literature review, and cross-segmentation analysis to produce validated, actionable insights

The research methodology underpinning this analysis combines a multi-source evidence synthesis with expert-validated interpretation to ensure actionable rigor. Primary inputs include structured interviews with oncologists, pharmacy directors, payer representatives, and clinical operations leaders, which inform real-world care patterns, adoption barriers, and evidence needs. Secondary sources encompass peer-reviewed clinical literature, clinical trial registries, regulatory guidance documents, and aggregated public filings to construct an accurate picture of therapeutic mechanisms, safety profiles, and trial endpoints.

Analytical techniques applied include cross-segmentation mapping to align therapeutic modalities with administration routes, distribution channels, disease stages, end-user contexts, and histologic subtypes. Scenario analysis and sensitivity checks were used to test assumptions around supply chain disruptions and policy shifts, while qualitative synthesis grounded recommendations in stakeholder priorities and operational feasibility. Wherever possible, findings were triangulated across multiple data sources and validated through expert advisory consultations.

The research team adhered to transparent documentation of data provenance, interview protocols, and analytic assumptions to ensure reproducibility and to support client-specific customizations. Ethical considerations guided stakeholder engagement, and all primary data collection was conducted with appropriate confidentiality measures. This methodological foundation supports robust, pragmatic insights for stakeholders navigating the evolving stomach cancer treatment landscape.

Conclusive synthesis emphasizing the necessity of integrated clinical, commercial, and operational strategies to translate innovation into accessible and sustainable stomach cancer care

Stomach cancer care is moving toward a more personalized, multi-modality model that requires alignment across clinical evidence, supply chains, payer frameworks, and care delivery systems. Advances in targeted therapies and immuno-oncology are creating new clinical possibilities, but realizing their full potential depends on coordinated investments in diagnostics, patient support, and real-world evidence generation. Additionally, operational factors such as administration routes, distribution channels, and regional regulatory differences will materially influence the pace and breadth of adoption.

Stakeholders that proactively integrate scientific strategy with pragmatic commercialization and supply chain planning will be best positioned to deliver meaningful improvements in outcomes. This requires a holistic perspective that considers histologic heterogeneity, disease stage, and end-user capabilities while also anticipating policy and trade developments that affect access. In short, success will be defined by the ability to translate therapeutic promise into accessible, economically sustainable care pathways that are responsive to evolving clinical and payer expectations.

As the field evolves, continuous monitoring of clinical trial results, regulatory decisions, and real-world performance will be essential to refine strategies and to capture windows of opportunity for differentiated therapies. The path forward combines scientific rigor with operational adaptability to ensure that innovation equitably reaches patients who need it most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of PD-1 and PD-L1 inhibitors in first-line gastric cancer treatment
  • 5.2. Integration of molecular biomarker screening to personalize gastric cancer therapies
  • 5.3. Increasing use of liquid biopsy for early detection and monitoring of tumor recurrence
  • 5.4. Development of FGFR2 targeting agents for advanced gastric cancer patients with receptor amplification
  • 5.5. Expansion of minimally invasive robotic surgery to improve postoperative outcomes in gastric cancer
  • 5.6. Utilization of real-world evidence to optimize treatment sequencing in metastatic gastric cancer
  • 5.7. Growth of combination immunotherapy and chemotherapy regimens in advanced stomach cancer management
  • 5.8. Rising investment in AI-enabled endoscopic systems to enhance early gastric cancer diagnosis accuracy
  • 5.9. Emergence of CAR-T cell therapies targeting Claudin 18.2 in refractory gastric tumors
  • 5.10. Impact of evolving reimbursement policies on accessibility of novel gastric cancer treatments across markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Stomach Cancer Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Fluorouracil-Based
    • 8.1.2. Platinum-Based
    • 8.1.3. Taxane-Based
  • 8.2. Immunotherapy
    • 8.2.1. Ctla-4 Inhibitors
    • 8.2.2. Pd-1 Inhibitors
  • 8.3. Radiotherapy
    • 8.3.1. Brachytherapy
    • 8.3.2. External Beam
  • 8.4. Surgery
    • 8.4.1. Partial Gastrectomy
    • 8.4.2. Total Gastrectomy
  • 8.5. Targeted Therapy
    • 8.5.1. Egfr Inhibitors
    • 8.5.2. Her2 Inhibitors
    • 8.5.3. Vegf Inhibitors

9. Stomach Cancer Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Stomach Cancer Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Stomach Cancer Treatment Market, by Stage

  • 11.1. Stage I
  • 11.2. Stage Ii
  • 11.3. Stage Iii
  • 11.4. Stage Iv

12. Stomach Cancer Treatment Market, by End User

  • 12.1. Homecare
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Stomach Cancer Treatment Market, by Histologic Type

  • 13.1. Adenocarcinoma
  • 13.2. Carcinoid Tumors
  • 13.3. Gist
  • 13.4. Lymphoma

14. Stomach Cancer Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Stomach Cancer Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Stomach Cancer Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. F. Hoffmann-La Roche AG
    • 17.3.2. Bristol-Myers Squibb Company
    • 17.3.3. Merck Sharp & Dohme Corp.
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. Novartis AG
    • 17.3.6. Takeda Pharmaceutical Company Limited
    • 17.3.7. Daiichi Sankyo Company, Limited
    • 17.3.8. Sanofi S.A.
    • 17.3.9. Pfizer Inc.
    • 17.3.10. Amgen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. STOMACH CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRI